Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company") (NASDAQ
MKT: PTX), a specialty pharmaceutical company, today announced the
appointment of Sanjay Patel as Chief Financial Officer.
Mr. Patel brings to Pernix over 15 years of investment banking,
institutional investment and public policy experience. Mr. Patel has
assisted specialty pharmaceutical and healthcare companies raise more
than $7 billion in initial public offerings, follow-on offerings, debt
offerings and private placements. He has served as a financial advisor
on a variety of mergers, acquisitions and strategic alliances. While on
the buyside at a $5bn fund, Mr. Patel was responsible for a global
portfolio of generic and specialty pharmaceutical holdings. He also
worked with the William J. Clinton Foundation and the Global Fund to
negotiate and implement long-term supply agreements for HIV and malaria
drugs throughout the developing world. Mr. Patel is a CFA Charterholder
and received a Bachelor of Science in Biology and Molecular Genetics
with Honors from McGill University in Montreal, Canada.
"I am pleased to welcome Sanjay to the Pernix senior executive team.
Sanjay's finance and investment banking credentials will provide
valuable support as we seek to acquire additional specialty products and
businesses," said Doug Drysdale, President and CEO of Pernix.
About Pernix Therapeutics Holdings, Inc.
Pernix Therapeutics is a specialty pharmaceutical company primarily
focused on the sales, marketing, manufacturing and development of
branded pharmaceutical products. The Company markets a portfolio of
branded products, including: CEDAX®, an antibiotic for middle ear
infections and a number of treatments for cough and cold conditions
including ZUTRIPRO®, REZIRA® and VITUZ®. The Company also markets
SILENOR, a non-narcotic product for the treatment of insomnia and
KHEDEZLA, a treatment for major depressive disorder. The Company
promotes its branded products to physicians through its Pernix sales
force and markets its generic portfolio through its wholly owned
subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals.
Founded in 1996, the Company is based in Morristown, New Jersey.
Additional information about Pernix is available on the Company's
website located at www.pernixtx.com.
[ Back To NFVZone's Homepage ]